Check 35,000+ stocks against 26 valuation models and 37 quality factors

Emergent Biosolutions Inc (EBS) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Emergent Biosolutions Inc $20.01, price $6.67, upside +200.0%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN US29089Q1058

Thin data Sep 23, 2026

Emergent Biosolutions Inc

EBS · US

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value $20.01 · Strongly undervalued (+200%)

!Quality 55/100

!Weak Growth (revenue 5y −14.0 %/yr)

!Loss over the last twelve months · -1.3% net margin (TTM) · fiscal year 2025 7.1%

✓Moderate debt · generates free cash flow

!Mixed vs. peers (7/13)

!Narrow moat 27/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear $15.01 to bull $25.01 Growth analysisrevenue history, year by year Quality 55/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Emergent Biosolutions Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $1.50 – $66.05 · fair‑value band $15.01 – $25.01 · the $6.67 price screens below the $20.01 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.

Follow Emergent Biosolutions in your weekly email

Every Wednesday you see whether Emergent Biosolutions is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Stock analysis

Emergent Biosolutions Inc (EBS) currently trades at $6.67, while our model-based Fair Value estimate is $20.01, implying the stock looks roughly 66.7% undervalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of $36.80 per share, and 24 of the 24 models we run sit above the $6.67 price.

Bear case: the Asset-Based group reads lowest at $6.79, and 0 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: $15.01 (bear) to $25.01 (bull), the price of $6.67 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Emergent Biosolutions Inc reported revenue of $743M in FY2025 versus $1.8B in FY2021, a compound −19.6%/yr. Reported net income was $52.6M in FY2025, compounding −30.0%/yr from FY2021.

Key figures

Market cap $413M · P/S ratio 0.61 · EPS (TTM) $−0.1900 · Net margin 7.1% · Return on equity −1.6% · Return on assets (EBIT) −6.6% · Operating margin 6.8% · Revenue (TTM) $677M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 52% below its 52-week high and 50% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 200%, EBS screens cheaper than that median.

Fair Value models

Bear $15.01 Fair Value $20.01 Bull $25.01

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $31.84 $53.98 $85.95 79

Growth DCF $31.60 $51.77 $79.49 77

Owner Earnings $27.52 $47.19 $75.61 75

All 24 models by family

DCF Models

FCF DCF $31.84 $53.98 $85.95 79

Owner Earnings $27.52 $47.19 $75.61 75

5Y Revenue Exit $19.37 $32.96 $50.26 71

5Y EBITDA Exit $31.07 $56.09 $86.22 74

5Y P/E Exit $17.15 $28.57 $40.72 70

10Y Revenue Exit $23.36 $36.80 $55.20 66

10Y EBITDA Exit $30.86 $51.92 $81.61 67

10Y P/E Exit $22.57 $33.93 $48.19 64

Earnings-Based

Graham-Dodd $6.93 $27.65 $37.58 64

Lynch FV $6.86 $9.81 $12.75 61

PEG = 1.0 $6.86 $9.81 $12.75 57

EPV $5.30 $6.99 $8.40 74

Multiples

P/E Multiple $16.82 $22.43 $28.03 63

P/S Multiple $13.00 $17.33 $21.66 58

P/B Multiple $13.00 $17.33 $21.66 55

EV/EBIT $20.12 $29.20 $38.28 65

EV/EBITDA $34.81 $48.79 $62.76 67

EV/Revenue $12.33 $20.66 $28.99 52

Asset-Based

NCAV (Graham) $5.06 $6.79 $10.13 54

Growth DCF

Growth DCF $31.60 $51.77 $79.49 77

Rev-Margin DCF $19.37 $33.22 $50.40 71

Economic Profit

Residual Income $8.38 $9.11 $11.12 71

ROIC Compounder $5.30 $6.99 $8.40 72

Growth Earnings

Growth-Adj P/E $12.43 $17.76 $23.09 67

Open the full fair value analysis →

Notify me when EBS reaches fair value

Put EBS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 55/100

Of which business quality 55 · Market factors (momentum, volatility) 11

Profitability 41

Margins and returns on capital today

Quality Growth 60

Are margins and returns improving?

Cashflow 91

Earnings quality: real cash, not paper profit

Fin. Strength 28

Balance sheet, leverage, solvency risk

Investment 100

Disciplined investing over empire-building

Low Volatility 0

Calm price path (market factor)

Momentum 14

Price trend over the last 3–12 months (market factor)

52W Momentum 18

Distance to the 52-week high (market factor)

Net Issuance 25

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100

Revenue is shrinking: the last year, the last three and the last five years are all negative.

Revenue growth 1 year

−28.8%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−12.7%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−14.0%

Start year 2020 (pandemic). Over 10 years: +4.3% a year

Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+12.4%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.

−22.8%

Earnings growth per share plus dividend.

Earnings per share, growth per year−22.8%

Dividend (yield on the price)0.0%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−26% vs −1%, slowing

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.28% → 15%

Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

−1.3%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −3.6% a year for the price.

Watch EBS, get fair value alerts →

Compare Emergent Biosolutions Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks

Beats the industry median on 7/12 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 55 · Above median

Fair Value upside +200% · Top 25%

Profitability

Return on assets 3% · Above median

Net margin (TTM) −1% · Below median

Operating margin (TTM) 7% · Below median

Growth and dividend

Revenue growth −30% · Bottom 25%

Balance sheet

Debt / equity 1.10× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.79× · Cheapest 25%

P/S (TTM) 0.61× · Cheapest 25%

P/FCF 2.6× · Pricier than median

EV/EBITDA 4.7× · Cheapest 25%

PEG 0.38× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)100 · sector 14

FUTURE (revenue growth)0 · sector 21

PAST (return on equity)0 · sector 27

HEALTH (low debt)45 · sector 96

DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€133.15	€108.70	−18%
Takeda Pharmaceutical Company TAK	$18.95	$11.29	−40%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥45.58	¥50.14	+10%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,865	₹1,979	+6%
Galderma Group GALD	CHF 163.80	CHF 109.88	−33%
Haleon plc HLN	$9.25	$8.50	−8%
Teva Pharmaceutical Industries Limited TEVA	$39.52	$20.75	−47%
Sandoz Group SDZ	CHF 70.76	CHF 40.16	−43%
Zoetis Inc ZTS	$72.86	$108.48	+49%
Hansoh Pharmaceutical Group 3692	HK$35.34	HK$38.87	+10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Emergent Biosolutions Inc · Fair Value
$20.01 +67%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/EBS" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Emergent Biosolutions Inc · Fair Value</span><br><b style="font-size:20px">$20.01</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+67%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Emergent Biosolutions Inc Fair Value". https://www.fairvalue-calculator.com/stock/EBS

Frequently asked questions

Is Emergent Biosolutions Inc (EBS) overvalued or undervalued?

As of Sep 23, 2026, our model estimates a fair value of $20.01 versus a price of $6.67, about +200% upside (undervalued).

What is the fair value of EBS?

Our model-based fair value for Emergent Biosolutions Inc is $20.01 (as of Sep 23, 2026), built from audited fundamentals. The current price: $6.67.

What is the quality score of EBS?

Emergent Biosolutions Inc has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Emergent Biosolutions Inc (EBS)?

Our model-based price target is the fair value of $20.01 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario $15.01, optimistic scenario $25.01. It is a calculation from audited fundamentals, not an analyst target.

What is the Emergent Biosolutions Inc stock forecast for 2026?

Our models put fair value at $20.01, about +200% upside versus a price of $6.67 (undervalued). Cautious scenario $15.01, optimistic scenario $25.01. The calculation is refreshed regularly with new filings.

What is the revenue of Emergent Biosolutions Inc (EBS)?

Emergent Biosolutions Inc reported trailing-twelve-month revenue of about $677M (latest available figure, as of Sep 23, 2026).

What growth is priced into Emergent Biosolutions Inc (EBS)?

For today's price to be fair in a discounted-cash-flow model, Emergent Biosolutions Inc would have to grow free cash flow by -1.3 % per year for five years (discount rate 13.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -14.0 % per year. As of Sep 23, 2026.

What discount rate (WACC) does the fair value of EBS use?

Our models discount Emergent Biosolutions Inc at 13.7 %: a base by market capitalisation (small), damped by beta 2.33, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Emergent Biosolutions Inc that is -1.3 % per year a year over ten years, using the same discount rate (13.7 %) and the same formula as our fair value.

How much growth has Emergent Biosolutions Inc (EBS) delivered so far?

Over the past 5 years revenue at Emergent Biosolutions Inc grew -14.0 % a year. The price currently implies -1.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Emergent Biosolutions Inc (EBS) growing?

The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Emergent Biosolutions Inc (-1.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Emergent Biosolutions Inc (EBS)?

The free-cash-flow yield on the price is 41.46 %: that much free cash flow Emergent Biosolutions Inc produces per unit of market value. When it exceeds the discount rate of our models (13.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Emergent Biosolutions Inc (EBS)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Emergent Biosolutions Inc it is $20.01 per share (as of Sep 23, 2026), against a price of $6.67. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is Emergent Biosolutions Inc stock overvalued or undervalued in 2026?

As of Sep 23, 2026, EBS trades below its calculated fair value: price $6.67, fair value $20.01, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of EBS?

No. The price is what the market pays today ($6.67); the fair value is what the company's own numbers justify ($20.01). For Emergent Biosolutions Inc the two are $13.34 per share apart. That gap is exactly why we show both numbers side by side.

How much is Emergent Biosolutions Inc worth?

The market values Emergent Biosolutions Inc at about $413M (market capitalisation, as of Sep 23, 2026). Per share that is $6.67; our models calculate a fair value of $20.01 per share.

What do the bullish and bearish scenarios say about EBS?

Our models span a range for Emergent Biosolutions Inc: cautious scenario $15.01, base $20.01, optimistic $25.01 per share (as of Sep 23, 2026, price $6.67). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the PEG ratio of EBS?

The PEG ratio of Emergent Biosolutions Inc is 0.38 (P/E divided by earnings growth, as of Sep 23, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.

How solid is the balance sheet of Emergent Biosolutions Inc (EBS)?

Balance-sheet figures for Emergent Biosolutions Inc (as of Sep 23, 2026): return on equity −1.6%, debt of 1.10 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.

How far is EBS from its 52-week high?

Emergent Biosolutions Inc trades at $6.67, about 52% below its 52-week high of $13.90 and 50% above the low of $4.45 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $20.01 is for.

Which stocks are comparable to Emergent Biosolutions Inc?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Emergent Biosolutions Inc stock attractive at the current price?

The data as of Sep 23, 2026: price $6.67, calculated fair value $20.01 (+200%), Quality Score 55/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of EBS calculated?

We run Emergent Biosolutions Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $20.01, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.1 % above its aggregate fair value. Emergent Biosolutions Inc currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Emergent Biosolutions Inc (EBS)?

The closing price on Sep 23, 2026 was $6.67. Our model-based fair value is $20.01, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Emergent Biosolutions Inc right now?

The price is below even our cautious bear case ($15.01). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Emergent Biosolutions Inc

How large is the market capitalisation of Emergent Biosolutions Inc (EBS)?

The market capitalisation of Emergent Biosolutions Inc is $413M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Emergent Biosolutions Inc (EBS)?

The price-to-sales ratio of Emergent Biosolutions Inc is 0.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Emergent Biosolutions Inc (EBS)?

Earnings per share at Emergent Biosolutions Inc are $−0.1900. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Emergent Biosolutions Inc (EBS)?

The net margin of Emergent Biosolutions Inc is 7.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Emergent Biosolutions Inc (EBS)?

The return on equity (ROE) of Emergent Biosolutions Inc is −1.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Emergent Biosolutions Inc (EBS)?

On an EBIT basis the return on assets of Emergent Biosolutions Inc is −6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Emergent Biosolutions Inc (EBS)?

The operating margin of Emergent Biosolutions Inc is 6.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Emergent Biosolutions Inc (EBS)?

Revenue at Emergent Biosolutions Inc is growing −29.7% versus a year earlier (3y avg −12.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Emergent Biosolutions Inc (EBS)?

Earnings per share at Emergent Biosolutions Inc are growing −93.8% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Emergent Biosolutions Inc (EBS) carry?

The net debt of Emergent Biosolutions Inc is $367M (fiscal year 2025, ≈ 2.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Emergent Biosolutions Inc in the live analysis

One click puts Emergent Biosolutions Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.